{"id":18691,"date":"2023-01-25T10:41:20","date_gmt":"2023-01-25T10:41:20","guid":{"rendered":"https:\/\/clinlabint.com\/?p=18691"},"modified":"2023-01-25T10:41:20","modified_gmt":"2023-01-25T10:41:20","slug":"protondx-appoints-new-head-of-sales-for-european-commercial-expansion","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/protondx-appoints-new-head-of-sales-for-european-commercial-expansion\/","title":{"rendered":"ProtonDx appoints new head of sales for European commercial expansion"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

ProtonDx appoints new head of sales for European commercial expansion<\/h1>\/ in E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

ProtonDx, an in vitro diagnostics company designing, manufacturing and marketing rapid, accurate, multi-pathogen, point-of-need diagnostic solutions, has appointed Leigh Howes as its new head of sales.<\/h3>\n

<\/p>\n

Howes is a commercially astute leader with more than 20 years of experience in the life science, diagnostics and clinical markets. He brings a proven track record of success to ProtonDx, delivering consistent growth, focused on achievement and a structured approach to strategy deployment.<\/p>\n

As leader of the Commercial Sales team, Howes will have a pivotal role in setting-up distribution partners and direct sales in Europe and countries that accept the CE-IVD mark. This follows ProtonDx\u2019s successful CE IVD marking for its innovative Dragonfly in vitro diagnostic system earlier this year.<\/p>\n

Howes commented: \u201cI am honoured and thrilled to be joining ProtonDx, and look forward to working with a talented and highly dedicated team. By introducing molecular testing at the point-of-care, our flagship product, Dragonfly, delivers numerous potential benefits for healthcare professionals and caregivers \u2013 ultimately improving patient outcomes. I look forward to helping realise ProtonDx and Dragonfly\u2019s huge potential and to build on the Company\u2019s existing successes while solidifying its position as a significant commercial player.\u201d<\/p>\n

Dragonfly is a portable, rapid molecular diagnostic system able to identify multiple viral pathogens at the point of need. Its revolutionary approach allows severe acute respiratory syndrome coronavirus 2 (SARS CoV 2), influenza A virus (IAV), influenza B virus (IBV), respiratory syncytial virus (RSV) and human rhinovirus (HRV) to be detected in a single test. The system is poised to help revolutionise rapid infectious disease detection and tracking worldwide<\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n

Leigh Howes, new head of sales at ProtonDx<\/em><\/p>\n<\/div><\/section>
\n